Inozyme Pharma Future Growth
Future criteria checks 0/6
Inozyme Pharma is forecast to grow earnings and revenue by 4.2% and 78.4% per annum respectively while EPS is expected to grow by 18.4% per annum.
Key information
4.2%
Earnings growth rate
18.4%
EPS growth rate
Biotechs earnings growth | 30.3% |
Revenue growth rate | 78.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 15 | -154 | -181 | -151 | 7 |
12/31/2025 | N/A | -133 | -145 | -132 | 7 |
12/31/2024 | N/A | -107 | -113 | -98 | 7 |
6/30/2024 | N/A | -89 | -86 | -86 | N/A |
3/31/2024 | N/A | -77 | -78 | -77 | N/A |
12/31/2023 | N/A | -71 | -71 | -71 | N/A |
9/30/2023 | N/A | -68 | -67 | -67 | N/A |
6/30/2023 | N/A | -68 | -63 | -62 | N/A |
3/31/2023 | N/A | -68 | -62 | -61 | N/A |
12/31/2022 | N/A | -67 | -58 | -58 | N/A |
9/30/2022 | N/A | -67 | -57 | -57 | N/A |
6/30/2022 | N/A | -65 | -55 | -55 | N/A |
3/31/2022 | N/A | -62 | -50 | -50 | N/A |
12/31/2021 | N/A | -57 | -49 | -48 | N/A |
9/30/2021 | N/A | -49 | -46 | -46 | N/A |
6/30/2021 | N/A | -63 | -44 | -43 | N/A |
3/31/2021 | N/A | -60 | -43 | -42 | N/A |
12/31/2020 | N/A | -56 | -37 | -36 | N/A |
9/30/2020 | N/A | -52 | -31 | -30 | N/A |
6/30/2020 | N/A | -28 | -24 | -24 | N/A |
3/31/2020 | N/A | -22 | -20 | -20 | N/A |
12/31/2019 | N/A | -20 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INZY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INZY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INZY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INZY is forecast to have no revenue next year.
High Growth Revenue: INZY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INZY's Return on Equity is forecast to be high in 3 years time